The Silver Tsunami Prescription: A Comprehensive Analysis of Approval Delays and Innovation Assessment in China's Novel Geriatric Drugs (2005–2024)

This cross‐sectional study aims to demonstrate the impact of China's 2015 review and approval reform on the delays in market entry for novel geriatric drugs, as well as the capability of domestic innovation in developing geriatric drugs. We analyzed the novel geriatric drugs approved by the US Food and Drug Administration (FDA) between 2005 and 2024 to assess the drug lags in China by using the EU and Japan as comparators. During this period, the FDA approved a total of 183 novel drugs targeting geriatric diseases, of which 109 were also approved by the NMPA. Post‐reform, China's absolute approval lag decreased significantly, with median relative lag narrowing from 53.9 to 29.9 months. However, China's lag remained longer than the EU and Japan, driven by submission delays. Domestic innovative drug approvals surged post‐reform, yet oncology dominated, overshadowing high‐burden conditions like neurological disorders, cardiovascular disease, and respiratory diseases. Expedited programs reduced development duration (conditional approval: 49.4 vs. regular 70.9 months), but review times lagged behind the FDA (16.1 vs. 11.1 months). This study also discusses the considerations of China's regulatory agency regarding current issues in geriatric drug development and future regulatory plans. Future regulatory efforts in China should focus on promoting patient‐centric approaches, optimizing trial designs (including clinical pharmacology modeling and artificial intelligence), and incorporating real‐world evidence to address the unique needs of older adults. These measures will be crucial in ensuring equitable access to innovative therapies and mitigating the impact of the “silver tsunami” on health outcomes for China's rapidly aging population.